The Neuropathy Breakthrough Mainstream Medicine Overlooked: The High-Concentration Capsaicin Protocol

There is a treatment for neuropathic foot pain that is FDA-approved, non-opioid, non-systemic, and applied in a doctor’s office in under an hour — and yet many patients living with burning feet have never been offered it. It is the high-concentration 8% capsaicin patch. This article explains how it works, what the clinical evidence genuinely shows, why it often takes more than one treatment to see the full benefit, and how it fits into a repair-focused protocol. It also draws a careful line between what is proven and what is still being studied — because that distinction is exactly what “mainstream medicine missed” conversations tend to blur.

A note on numbers, up front

You may have seen a very high success figure attached to this protocol. In the interest of honesty: the controlled clinical trials of the 8% capsaicin patch show modest but statistically significant pain relief, not near-universal cure. Any higher real-world success rate reported by an individual clinic reflects that clinic’s own patient population, protocol, and outcome definition — it is a practice observation, not a figure from the randomized trials, and it should be understood that way. What follows sticks to the published science, then explains where clinical experience extends beyond it.

The receptor that makes chili peppers hot

Capsaicin is the compound that gives chili peppers their heat. It acts on a specific sensor on pain-sensing nerve endings called the TRPV1 receptor (transient receptor potential vanilloid 1). TRPV1 is the same receptor that responds to noxious heat — which is why capsaicin literally feels hot.

Low-dose capsaicin creams (0.025–0.075%) available over the counter provide mild, temporary relief and must be applied several times a day. The prescription 8% patch is a different order of magnitude — roughly a hundredfold more concentrated — and is designed to do something the creams cannot: temporarily defunctionalize the overactive pain fibers.

Defunctionalization: turning down an alarm that won’t stop

In chronic neuropathy, the small C-fibers in the skin become pathologically hyperexcitable. They fire pain signals continuously, even without a real stimulus — the alarm is stuck on. A single, controlled 30-minute application of the 8% patch delivers enough capsaicin to overstimulate those TRPV1-bearing endings and then reversibly quiet them. The nerve endings retract and stop transmitting their runaway pain signals; over the following weeks and months they gradually recover. Crucially, controlled studies found this happens without degrading normal sensation — patients retained their ability to feel sharp, warm, cold, and vibration stimuli.

Because the treatment is topical and non-systemic, it sidesteps the sedation, dizziness, and cognitive fog that limit oral neuropathic-pain drugs. The main side effect is temporary burning and redness at the application site, which is why the patch is applied in a clinical setting, often with skin pre-treatment for comfort.

What the evidence shows

The 8% patch first earned FDA approval in 2009 for postherpetic neuralgia (the lingering nerve pain after shingles). In 2020, on the strength of the pivotal STEP trial led by Dr. David Simpson, the FDA extended approval to painful diabetic peripheral neuropathy of the feet. In STEP, a single 30-minute treatment produced a statistically significant reduction in average daily pain compared with placebo. A separate 52-week study (PACE) confirmed that repeated treatments were well tolerated over a full year, with no worsening of sensory function.

This is the honest headline: the patch reliably and safely reduces pain for a meaningful share of patients, and it can be repeated approximately every three months.

Why persistence matters

One reason patients — and sometimes physicians — give up too soon is that they expect a single patch to do everything. The data and clinical experience both suggest the benefit often builds across successive cycles. Each treatment quiets the overfiring fibers again and extends the window of reduced pain. For a chronic condition that took years to develop, expecting resolution from one application is unrealistic; the protocol is designed around repeated, spaced treatments.

The investigational frontier: can it help nerves regrow?

Here is where the science is genuinely exciting but not yet settled. Because capsaicin causes nerve endings to retract and then regenerate, researchers have asked whether repeated treatment might not just relieve pain but actually encourage healthier re-innervation of the skin — in other words, whether it could be disease-modifying. A randomized trial in the United Kingdom is formally testing exactly this question in diabetic neuropathy.

Until that kind of study reports, the responsible position is: the 8% patch is proven for pain relief, and its potential to modify the underlying nerve damage is a promising hypothesis under active investigation. Regenerve’s approach uses the pain-relief window the patch creates as the foundation for the repair-focused steps — orthobiologics and mitochondrial and metabolic support — that aim at the nerve itself. Those regenerative components, as covered in the protocol article, are themselves emerging and individualized rather than guaranteed.

Who is a candidate

The patch is used for localized neuropathic pain, classically in the feet for diabetic neuropathy and in the affected area for postherpetic neuralgia. Suitability depends on a physician’s evaluation of the pain distribution, skin integrity, and overall picture. As with any treatment, it works best as part of a plan that also addresses the root drivers of the neuropathy rather than as a standalone fix.

Frequently asked questions

Key takeaways

• The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet (2020) and postherpetic neuralgia (2009).
• It works by reversibly quieting overfiring TRPV1 pain fibers, without degrading normal sensation, and without systemic side effects.
• Trial evidence supports real but modest pain relief; benefit often builds across repeated treatments.
• Whether it can help nerves regenerate is a legitimate, still-unproven hypothesis under study.
• It works best inside a plan that also treats the neuropathy’s root causes.

Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any treatment without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902.

References

1. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
2. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for painful diabetic peripheral neuropathy of the feet. 2020; original PHN approval 2009.
3. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
4. Anand P, Bley K. Topical capsaicin for pain management: mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
5. Abrams RMC, et al. A critical review of the capsaicin 8% patch for diabetic peripheral neuropathy of the feet. Expert Rev Neurother. 2021.